Cyclin-dependent kinase inhibitors as marketed anticancer drugs: Where are we now? A short survey

Molecules

Volumn 19, Issue 9, 2014, Pages 14366-14382

  Mariaule, Gaëlle ^a,b   Belmont, Philippe ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Allosteric site; Anticancer; ATP non competitive; ATP competitive; CDK; Clinical evaluation; Heterocycle; Inhibitor; Kinase

Indexed keywords

ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CYCLIN DEPENDENT KINASE; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; CELL CYCLE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; HUMAN; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL CYCLE; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; HUMANS; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84907105038     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules190914366     Document Type: Article

References (76)

1. Matthews, D.J.; Gerritsen, M.E. Targeting Protein Kinases for Cancer Therapy; John Wiley & sons, Inc.: Hoboken, NJ, USA, 2010.
2. Moen, M.D.; McKeage, K.; Plosker, G.L.; Siddiqui, M.A. Imatinib: A review of its use in chronic myeloid leukaemia. Drugs 2007, 67, 299-320.
3. Meijer, L. Le cycle de division cellulaire et sa régulation. Oncologie 2003, 5, 311-326.
4. Manning, G.; Whyte, D.B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
5. Schwob, E. Nobel Prize in Medicine 2001: The universal key to cell division. Bull. Cancer 2001, 88, 937.
6. Malumbres, M.; Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 2005, 30, 630-641.
7. Satyanarayana, A.; Kaldis, P. Mammalian cell-cycle regulation: Several CDKs, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009, 28, 2925-2939.
8. Kohoutek, J.; Blazek, D. Cyclin K goes with CDK12 and CDK13. Cell Div. 2012, doi:10.1186/1747-1028-7-12.
9. De Bondt, H.L.; Rosenblatt, J.; Jancarik, J.; Jones, H.D.; Morgan, D.O.; Kim, S.H. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363, 595-602.
10. Morgan, D.O. Principles of CDK regulation. Nature 1995, 374, 131-134.
11. Solomon, M.J. Activation of the various cyclin/CDC2 protein kinases. Curr. Opin. Cell Biol. 1993, 5, 180-186.
12. Karlsson-Rosenthal, C.; Millar, J.B. CDC25: Mechanisms of checkpoint inhibition and recovery. Trends Cell Biol. 2006, 16, 285-292.
13. Elledge, S.J.; Winston, J.; Harper, J.W. A question of balance: The role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Cell Biol. 1996, 6, 388-392.
14. Kaldis, P. The CDK-activating kinase (CAK): From yeast to mammals. Cell. Mol. Life Sci. 1999, 55, 284-296.
15. Galons, H.; Oumata, N.; Meijer, L. Cyclin-dependent kinase inhibitors: A survey of recent patent literature. Expert Opin. Ther. Pat. 2010, 20, 377-404.
16. Sharma, P.S.; Sharma, R.; Tyagi, R. Inhibitors of cyclin dependent kinases: Useful targets for cancer treatment. Curr. Cancer Drug Targets 2008, 8, 53-75.
17. Cicenas, J.; Valius, M. The CDK inhibitors in cancer research and therapy. J. Cancer Res. Clin. Oncol. 2011, 137, 1409-1418.
18. Fischer, P.M.; Gianella-Borradori, A. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs 2003, 12, 955-970.
19. Canavese, M.; Santo, L.; Raje, N. Cyclin dependent kinases in cancer: Potential for therapeutic intervention. Cancer Biol. Ther. 2012, 13, 451-457.
20. Diaz-Padilla, I.; Siu, L.L.; Duran, I. Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Investig. New Drugs 2009, 27, 586-594.
21. Lapenna, S.; Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 2009, 8, 547-566.
22. Galons, H.; Oumata, N.; Gloulou, O.; Meijer, L. Cyclin-dependent kinase inhibitors closer to market launch? Expert Opin. Ther. Pat. 2013, 23, 945-963.
23. Stone, A.; Sutherland, R.L.; Musgrove, E.A. Inhibitors of cell cycle kinases: Recent advances and future prospects as cancer therapeutics. Crit. Rev. Oncog. 2012, 17, 175-198.
24. De Azevedo, W.F.; Mueller-Dieckmann, H.J.; Schulze-Gahmen, U.; Worland, P.J.; Sausville, E.; Kim, S.H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA 1996, 93, 2735-2740.
25. Christian, B.A.; Grever, M.R.; Byrd, J.C.; Lin, T.S. Flavopiridol in the treatment of chronic lymphocytic leukemia. Curr. Opin. Oncol. 2007, 19, 573-578.
26. De Azevedo, W.F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S.H. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human CDK2 complexed with roscovitine. FEBS J. 1997, 243, 518-526.
27. Meijer, L.; Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. 2003, 36, 417-425.
28. Whittaker, S.R.; Walton, M.I.; Garrett, M.D.; Workman, P. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 2004, 64, 262-272.
29. Kaur, G.; Stetler-Stevenson, M.; Sebers, S.; Worland, P.; Sedlacek, H.; Myers, C.; Czech, J.; Naik, R.; Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. 1992, 84, 1736-1740.
30. Abate, A.A.; Pentimalli, F.; Esposito, L.; Giordano, A. ATP-noncompetitive CDK inhibitors for cancer therapy: An overview. Expert Opin. Investig. Drugs 2013, 22, 895-906.
31. Guha, M. Cyclin-dependent kinase inhibitors move into Phase III. Nat. Rev. Drug Discov. 2012, 11, 892-894.
32. Zeidner, J.F.; Foster, M.C.; Blackford, A.; Litzow, M.R.; Morris, L.; Strickland, S.A.; Lancet, J.E.; Bose, P.; Levy, M.Y.; Tibes, R.; et al. Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus "7+3" for adults with newly diagnosed acute myeloid leukemia (AML). In Proceedings of the American Society of Clinical Oncology Conference, Chicago, IL, USA, 3 June 2014.
33. McClue, S.J.; Blake, D.; Clarke, R.; Cowan, A.; Cummings, L.; Fischer, P.M.; MacKenzie, M.; Melville, J.; Stewart, K.; Wang, S.; et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 2002, 102, 463-468.
34. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J.P.; Blow, J.J.; Inagaki, N.; Inagaki, M.; Delcros, J.G.; Moulinoux, J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases CDC2, CDK2 and CDK5. FEBS J. 1997, 243, 527-536.
35. Cyclacel.com. Available online: http://www.cyclacel.com/research-programs-oncology-cyc202.shtml (accessed on 19 July 2014).
36. A Phase 3 Study Comparing Dinaciclib versus Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia (P07714 AM2). Available online: http://clinicaltrials.gov/ct2/show/NCT01580228?term=dinaciclib&rank=14 (accessed on 20 July 2014).
37. Mahadevan, D.; Plummer, R.; Squires, M.S.; Rensvold, D.; Kurtin, S.; Pretzinger, C.; Dragovich, T.; Adams, J.; Lock, V.; Smith, D.M.; et al. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. ESMO meeting. Ann. Oncol. 2011, 22, 2137-2143.
38. AT7519. Available online: http://clinicaltrials.gov/ct2/results?term=AT7519 (accessed on 20 July 2014).
39. Tong, W.G.; Chen, R.; Plunkett, W.; Siegel, D.; Sinha, R.; Harvey, R.D.; Badros, A.Z.; Popplewell, L.; Coutre, S.; Fox, J.A.; et al. Phase I and pharmacologic study of SNS-032, a potent and selective CDK2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. ASCO Annual Meeting. J. Clin. Oncol. 2010, 28, 3015-3022.
40. Guha, M. Blockbuster dreams for Pfizer's CDK inhibitor. Nat. Biotechnol. 2013, 31, 187, doi:10.1038/nbt0313-187a.
41. Smolewski, P. Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs 2008, 11, 204-214.
42. Phase 1 Study of Terameprocol (EM-1421) a Survivin and Cyclin-Dependent Kinase-1 (Cdc2) Inhibitor, in Patients with Leukemia. Available online: http://www.clinicaltrials.gov/ct2/results?term=EM-1421&Search=Search (accessed on 20 July 2014).
43. Cirstea, D.; Hideshima, T.; Santo, L.; Eda, H.; Mishima, Y.; Nemani, N.; Hu, Y.; Mimura, N.; Cottini, F.; Gorgun, G.; et al. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia 2013, 27, 2366-2375.
44. Phase 1 Open-label, Dose-escalation Clinical Study of the Safety and Tolerability of RGB-286638, a Novel, Multi-targeted Kinase Inhibitor, Administered to Patients with Selected, Relapsed or Refractory Hematological Malignancies. Available online: http://clinicaltrials.gov/ct2/show/NCT01168882?term=RGB-286638&rank=1 (accessed on 20 July 2014).
45. Agennix.com. Available online: http://www.agennix.com (accessed on 20 July 2014).
46. Kim, K.S.; Sack, J.S.; Tokarski, J.S.; Qian, L.; Chao, S.T.; Leith, L.; Kelly, Y.F.; Misra, R.N.; Hunt, J.T.; Kimball, S.D.; et al. Thio- and Oxoflavopiridols, Cyclin-Dependent Kinase 1-Selective Inhibitors: Synthesis and Biological Effects. J. Med. Chem. 2000, 43, 4126-4134.
47. Murthi, K.K.; Dubay, M.; McClure, C.; Brizuela, L.; Boisclair, M.D.; Worland, P.J.; Mansuri, M.M.; Pal, K. Structure-activity relationship studies of flavopiridol analogues. Bioorg. Med. Chem. Lett. 2000, 10, 1037-1041.
48. Joshi, K.S.; Rathos, M.J.; Mahajan, P.; Wagh, V.; Shenoy, S.; Bhatia, D.; Chile, S.; Sivakumar, M.; Maier, A.; Fiebig, H.H.; et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol. Cancer Ther. 2007, 6, 926-934.
49. Siemeister, G.; Lucking, U.; Wengner, A.M.; Lienau, P.; Steinke, W.; Schatz, C.; Mumberg, D.; Ziegelbauer, K. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol. Cancer Ther. 2012, 11, 2265-2273.
50. Lücking, U.; Jautelat, R.; Krüger, M.; Brumby, T.; Lienau, P.; Schäfer, M.; Briem, H.; Schulze, J.; Hillisch, A.; Reichel, A.; et al. The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-SCyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer. Chem Med Chem 2013, 8, 1067-1085.
51. William, A.D.; Lee, A.C.H.; Blanchard, S.; Poulsen, A.; Teo, E.L.; Nagaraj, H.; Tan, E.; Chen, D.; Williams, M.; Sun, E.T.; et al. Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa1(25),2(26),3,5,8,10,12(27),16,21, 23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma. J. Med. Chem. 2011, 54, 4638-4658.
52. Goh, K.C.; Novotny-Diermayr, V.; Hart, S.; Ong, L.C.; Loh, Y.K.; Cheong, A.; Tan, Y.C.; Hu, C.; Jayaraman, R.; William, A.D.; et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia 2012, 26, 236-243.
53. Poulsen, A.; William, A.; Blanchard, S.; Nagaraj, H.; Williams, M.; Wang, H.; Lee, A.; Sun, E.; Teo, E.-L.; Tan, E.; et al. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3). J. Mol. Model. 2013, 19, 119-130.
54. Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Available online: http://www.clinicaltrials.gov/ct2/show/NCT01699152?term=TG02&rank=2 (accessed on 24 July 2014).
55. Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Advanced Hematological Malignancies. Available online: http://www.clinicaltrials.gov/ct2/show/NCT01204164?term=TG02&rank=1 (accessed on 24 July 2014).
56. Phase II Study of Oral PHA-848125AC in Patients with Thymic Carcinoma Previously Treated with Chemotherapy. Available online: http://clinicaltrials.gov/show/NCT01011439 (accessed on 22 July 2014).
57. Besse, B.; Garassino, M.C.; Rajan, A.; Novello, S.; Mazieres, J.; Weiss, G.J.; Ciomei, M.; Martignoni, M.; Petroccione, A.; Davite, C.; et al. A phase II study of milciclib (PHA-848125AC) in patients with thymic carcinoma. In Proceedings of the American Society of Clinical Oncology Conference, Chicago, IL, USA, 30 May 2014.
58. Ciomei, M.; Scaburri, A. CDK Inhibitor for the Treatment of Mesothelioma. WO2010058006 A1, 27 May 2010.
59. Kurt, S. LEE011 CDK Inhibitor Showing Early Promise in Drug-Resistant Cancers. Oncol. Times 2014, 36, 39-40.
60. Macmillan Publishers Limited. CDK inhibitors speed ahead. Nat. Rev. Drug Discov. 2014, 13, 323. doi:10.1038/nrd4332.
61. A Phase 1b Study of LY2835219 in Combination with Endocrine Therapies for Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Available online: http://clinicaltrials.gov/ct2/show/NCT02057133?term=LY2835219&rank=5 (accessed on 25 July 2014).
62. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without LY2835219, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer. Available online: http://clinicaltrials.gov/ct2/show/NCT02107703?term=LY2835219&rank=9 (accessed on 25 July 2014).
63. Kubo, A.; Nakagawa, K.; Varma, R.K.; Conrad, N.K.; Cheng, J.Q.; Lee, W.C.; Testa, J.R.; Johnson, B.E.; Kaye, F.J.; Kelley, M.J. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. AACR meeting. Clin. Cancer Res. 1999, 5, 4279-4286.
64. Liggett, W.H., Jr.; Sidransky, D. Role of the p16 tumor suppressor gene in cancer. ASCO Annual Meeting. J. Clin. Oncol. 1998, 16, 1197-1206.
65. Musgrove, E.A.; Caldon, C.E.; Barraclough, J.; Stone, A.; Sutherland, R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11, 558-572.
66. Adams, P.D.; Sellers, W.R.; Sharma, S.K.; Wu, A.D.; Nalin, C.M.; Kaelin, W.G., Jr. Identification of a cyclin-CDK2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol. 1996, 16, 6623-6633.
67. Harper, J.W.; Adams, P.D. Cyclin-Dependent Kinases. Chem. Rev. 2001, 101, 2511-2526.
68. Gondeau, C.; Gerbal-Chaloin, S.; Bello, P.; Aldrian-Herrada, G.; Morris, M.C.; Divita, G. Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation. J. Biol. Chem. 2005, 280, 13793-13800.
69. Andrews, M.J.; McInnes, C.; Kontopidis, G.; Innes, L.; Cowan, A.; Plater, A.; Fischer, P.M. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Org. Biomol. Chem. 2004, 2, 2735-2741.
70. McInnes, C.; Andrews, M.J.; Zheleva, D.I.; Lane, D.P.; Fischer, P.M. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr. Med. Chem. Anti-Cancer Agents 2003, 3, 57-69.
71. Liu, S.; Premnath, P.N.; Bolger, J.K.; Perkins, T.L.; Kirkland, L.O.; Kontopidis, G.; McInnes, C. Optimization of Non-ATP Competitive CDK/Cyclin Groove Inhibitors through REPLACE-Mediated Fragment Assembly. J. Med. Chem. 2013, 56, 1573-1582.
72. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P.F.; Gilmore, T.; Graham, A.G.; Grob, P.M.; Hickey, E.R.; Moss, N.; Pav, S.; et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268-272.
73. Ohren, J.F.; Chen, H.; Pavlovsky, A.; Whitehead, C.; Zhang, E.; Kuffa, P.; Yan, C.; McConnell, P.; Spessard, C.; Banotai, C.; et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 2004, 11, 1192-1197.
74. Betzi, S.; Alam, R.; Martin, M.; Lubbers, D.J.; Han, H.; Jakkaraj, S.R.; Georg, G.I.; Schonbrunn, E. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem. Biol. 2011, 6, 492-501.
75. Ember, S.W.J.; Zhu, J.-Y.; Olesen, S.H.; Martin, M.P.; Becker, A.; Berndt, N.; Georg, G.I.; Schonbrunn, E. Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors. ACS Chem. Biol. 2014, 9, 1160-1171.
76. Martin, M.P.; Olesen, S.H.; Georg, G.I.; Schonbrunn, E. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem. Biol. 2013, 8, 2360-2365.